Sandra L. Kweder

Sandra L. Kweder

Auto-generated profile, based on publicly available information

Sandra L. Kweder

Office of Global Policy and Strategy US Food and Drug Administration Silver Spring Maryland USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MKMwango Kashoki
Mwango Kashoki
ZHZahra Hanaizi
Zahra Hanaizi
SYStella Yordanova
Stella Yordanova
RVRichard Veselý
Richard Veselý
CBChristelle Bouygues
Christelle Bouygues
SKSandra L. Kweder
Sandra L. Kweder
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust scientific and technical collaborations. As a window to the impact of these activities we compared the agencies’ decisions on drug marketing applications. Decisions were compared for 107 new drug applications with a regulatory outcome at both agencies in the period 2014–2016. Further analysis addressed individual applications for which the agencies had differing outcomes in terms of marketing approval, type of approval, and approved indication, including reasons underlying differences. The EMA and the FDA had high concordance (91–98%) in decisions on marketing approvals. Divergence in approval decisions, type of approval, and approved indication were primarily due to differences in agencies’ conclusions about efficacy based on review of the same data or differing clinical data submitted to support the application. This high rate of concordance suggests that engagement and collaboration on regulatory science has a positive impact.

6 December 2012 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SKS L Kweder
S L Kweder
SDS Dill
S Dill

26 August 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
TTTania Teixeira
Tania Teixeira
SKSandra L. Kweder
Sandra L. Kweder
ASAgnes Saint‐Raymond
Agnes Saint‐Raymond
There is talk of regulatory collaboration worldwide to protect public health and allow patients timely access to medicines. Here, we present the reality of the collaboration between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). This takes the form of near daily interactions, which may be less known outside of regulatory agencies. We present a review of what we call clusters, which involve the EMA, the FDA, and many other agencies under the umbrella of confidentiality arrangements. Through a survey of participants, we identified about 30 clusters of variable composition; these allow for the exchange of information and discussion among experts of applying regulatory science to common challenges in global drug development at every phase of its lifecycle and facilitate global medicines development.

1 May 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
JNJanet Nooney
Janet Nooney
STShannon Thor
Shannon Thor
CVCorinne de Vries
Corinne de Vries
JCJohn Clements
John Clements
LSLeyla Sahin
Leyla Sahin
SKSandra Kweder
Sandra Kweder
Scientists and regulators in Europe and the United States continue to seek methods and strategies to improve knowledge on rational use of medicines for pregnant and breastfeeding populations, an important subset of women’s health. Regulatory agencies have made strides toward improvement, but much more is needed. Recognizing the importance of international collaboration, we have begun to consider how to address these important public health issues more globally. The health of the child begins with the health of the mother.

5 February 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
DKDana Kappel
Dana Kappel
LSLeyla Sahin
Leyla Sahin
LYLynne Yao
Lynne Yao
STShannon Thor
Shannon Thor
SKSandra Kweder
Sandra Kweder
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust collaboration and dialogue around the need for data and the inclusion of pregnant and lactating individuals in clinical trials. Despite this collaboration, the two agencies have their own standards for the format and content of labeling for these populations. To understand these differences, the pregnancy and lactation labeling sections for 31 approved drugs were compared, and trends were assessed for use of language concordance and discordance related to use during pregnancy and lactation between the 2 agencies. Further analysis evaluated the presence of human data included in the labeling. The EMA and the FDA had high discordance between pregnancy and lactation labeling language, in 68% and 71% of labeling, respectively, and only 10% of pregnancy labeling and 16% of lactation labeling include human data. Concordance in labeling language is not the norm but occurs when there is a sizeable body of human data, animal data suggesting a particular safety issue, drug mechanism of action information, or disease‐specific considerations. This study highlights the need for more human data to inform prescribing decisions in these populations. The results also suggest that there is an opportunity for alignment in labeling across regions.